QT Imaging Partners with University of Oklahoma’s Health Stephenson Cancer Center

June 24, 2024

QT Imaging Holdings' Technology Advances Medical Imaging Research at the University of Oklahoma's Health Stephenson Cancer Center

QT Imaging Holdings, Inc. (NASDAQ:QTI) a medical device company engaged in research, development, and commercialization of innovative body imaging systems, is honored to partner with University of Oklahoma and OU Health Stephenson Cancer Center to advance and scale innovative research in medical imaging and to improve precision in cancer detection and treatment.

University of Oklahoma (OU) is home to the National Cancer Institute (NCI) designated OU Health Stephenson Cancer Center (SCC), and the National Institutes of Health Center of Biomedical Research Excellence (COBRE), Oklahoma Center of Medical Imaging for Translational Cancer Research. OU's medical imaging center recently launched its multidisciplinary biomedical research involving equipment and facilities that support project investigators in their quest to improve medical imaging use in cancer detection, diagnosis, and treatment. Innovative imaging modalities like QTI's Breast Acoustic CT™ technology, with its quantitative imaging predictive markers, will be used to provide an objective measure or index that can reduce subjectivity and improve consistency for medical image diagnosis.

"With the help of QTI's Breast Acoustic CT™ Scanner, we will be jumpstarting an expandable research platform meant to better understand how quantitative transmission ultrasound might advance cancer care in United States. As a translational research center, our role is to facilitate the movement of ideas between the biomedical engineering lab and the clinic, investigating how to improve cancer treatment and care," said Dr. Javier Jo, Director of the Oklahoma Center of Medical Imaging for Translational Cancer Research at OU.

"This collaboration presents an encouraging and validating opportunity for QTI's team to better understand the scope and potential of our technology," said Dr. Bilal Malik, QTI's Chief Science Officer. "In addition to exploring venues in breast cancer research with clinicians at the prestigious OU Health Stephenson Cancer Center, we look forward to collaborating with OU investigators to develop AI/ML-based algorithm tailored for our 3D images. We intend to take these algorithms through regulatory clearance pathways to ease the clinical workflows and to derive further insights from the inherently quantitative images of QTI's technology."

"QTI's technology provides an unprecedented view into breast anatomy and pathology by way of acoustic computed tomography (CT) scans. We plan to incorporate QTI's technology in our clinical research to validate its strengths, such as its ability to image frequently for disease progression as well as to be able to assess volumetric breast density without exposing the patient to radiation," said Dr. Robert Mannel, Director of the OU Health Stephenson Cancer Center.